Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free AEON Stock Alerts

AEON Biopharma (AEON) Competitors

AEON Biopharma logo
$0.73 +0.02 (+2.36%)
Closing price 07/2/2026 03:58 PM Eastern
Extended Trading
$0.74 +0.01 (+1.23%)
As of 07/2/2026 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AEON vs. EDSA, BYSI, EXOZ, PMVP, and BTMD

Should you buy AEON Biopharma stock or one of its competitors? MarketBeat compares AEON Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AEON Biopharma include Edesa Biotech (EDSA), BeyondSpring (BYSI), eXoZymes (EXOZ), PMV Pharmaceuticals (PMVP), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does AEON Biopharma compare to Edesa Biotech?

AEON Biopharma (NASDAQ:AEON) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 33.33%. Given Edesa Biotech's higher probable upside, analysts plainly believe Edesa Biotech is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

AEON Biopharma's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Edesa Biotech N/A -286.52%-75.36%

Edesa Biotech is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Edesa BiotechN/AN/A-$7.19M-$1.34N/A

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Edesa Biotech had 8 more articles in the media than AEON Biopharma. MarketBeat recorded 9 mentions for Edesa Biotech and 1 mentions for AEON Biopharma. Edesa Biotech's average media sentiment score of 1.44 beat AEON Biopharma's score of 0.92 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AEON Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AEON Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

Edesa Biotech beats AEON Biopharma on 8 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to BeyondSpring?

AEON Biopharma (NASDAQ:AEON) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
BeyondSpring N/A N/A -14.00%

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BeyondSpring is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
BeyondSpringN/AN/A-$1.01M-$0.14N/A

In the previous week, AEON Biopharma had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for AEON Biopharma and 0 mentions for BeyondSpring. AEON Biopharma's average media sentiment score of 0.92 beat BeyondSpring's score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
AEON Biopharma Positive
BeyondSpring Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

AEON Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Summary

AEON Biopharma beats BeyondSpring on 7 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to eXoZymes?

AEON Biopharma (NASDAQ:AEON) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

eXoZymes is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
eXoZymesN/AN/A-$9.16M-$1.14N/A

AEON Biopharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

AEON Biopharma's return on equity of 0.00% beat eXoZymes' return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
eXoZymes N/A -220.63%-141.26%

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, AEON Biopharma and AEON Biopharma both had 1 articles in the media. eXoZymes' average media sentiment score of 1.43 beat AEON Biopharma's score of 0.92 indicating that eXoZymes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AEON Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
eXoZymes
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AEON Biopharma and eXoZymes tied by winning 6 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to PMV Pharmaceuticals?

AEON Biopharma (NASDAQ:AEON) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
PMV PharmaceuticalsN/AN/A-$77.74M-$1.49N/A

AEON Biopharma's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
PMV Pharmaceuticals N/A -68.98%-62.70%

In the previous week, AEON Biopharma had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 1 mentions for AEON Biopharma and 0 mentions for PMV Pharmaceuticals. AEON Biopharma's average media sentiment score of 0.92 beat PMV Pharmaceuticals' score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
AEON Biopharma Positive
PMV Pharmaceuticals Neutral

PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 309.84%. Given PMV Pharmaceuticals' higher possible upside, analysts clearly believe PMV Pharmaceuticals is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
PMV Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

AEON Biopharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AEON Biopharma beats PMV Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to biote?

AEON Biopharma (NASDAQ:AEON) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

biote has higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
biote$192.22M0.42$27.05M$0.444.93

biote has a net margin of 8.29% compared to AEON Biopharma's net margin of 0.00%. AEON Biopharma's return on equity of 0.00% beat biote's return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
biote 8.29%-25.72%15.12%

In the previous week, AEON Biopharma had 1 more articles in the media than biote. MarketBeat recorded 1 mentions for AEON Biopharma and 0 mentions for biote. AEON Biopharma's average media sentiment score of 0.92 beat biote's score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
AEON Biopharma Positive
biote Neutral

biote has a consensus price target of $2.75, indicating a potential upside of 26.73%. Given biote's higher possible upside, analysts clearly believe biote is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
biote
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AEON Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, biote has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Summary

biote beats AEON Biopharma on 9 of the 14 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEON vs. The Competition

Export
MetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$18.52M$791.45M$7.16B$12.48B
Dividend YieldN/A4.84%2.66%6.52%
P/E Ratio4.071.6628.0224.70
Price / SalesN/A127.11540.3799.49
Price / CashN/A20.0649.2657.09
Price / Book-0.188.1710.966.46
Net Income-$36.63M-$3.71M$3.57B$337.01M
7 Day Performance1.39%2.59%2.12%1.69%
1 Month Performance1.43%4.41%5.25%3.81%
1 Year Performance-13.48%49.43%33.29%23.90%

AEON Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEON
AEON Biopharma
1.6314 of 5 stars		$0.73
+2.4%		N/A-13.5%$18.52MN/A4.075
EDSA
Edesa Biotech
1.5604 of 5 stars		$8.13
+6.0%		$5.00
-38.5%		+252.1%$72.28MN/AN/A20
BYSI
BeyondSpring
0.0591 of 5 stars		$1.75
-2.2%		N/A-16.9%$71.96M$1.75MN/A80
EXOZ
eXoZymes
0.9156 of 5 stars		$8.43
+0.1%		N/A-14.4%$71.49M$70KN/A29
PMVP
PMV Pharmaceuticals
3.2105 of 5 stars		$1.34
+3.9%		$5.00
+273.1%		+0.8%$71.47MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel